As semaglutide patents begin expiring across key markets, the real disruption isn't Novo Nordisk losing revenue — it's that...

Serina Therapeutics has secured FDA IND clearance for SER-252 and initiated dosing in a randomized Phase 1b study in...

Journey Medical reported full-year 2025 revenue of $61.9 million, up 10% year over year, driven by the first commercial...

Humacyte reported fourth-quarter and full-year 2025 results alongside a string of commercialization and regulatory moves for its bioengineered vessel...

Genfit reported full-year 2025 results and a 2026 outlook that pivots the company from a single‑asset story to a...

Adagene reported 2025 results and advanced its lead program, muzastotug (ADG126), a masked anti-CTLA-4 antibody now showing dose-dependent activity...

Semaglutide's patent expiration isn't a future problem for GLP-1 manufacturers — it's an active restructuring of the global obesity...

Nanobiotix has extended its cash runway into early 2028 and tightened strategic alignment around its lead asset, JNJ-1900 (formerly...

Nanobiotix closed 2025 with a materially de-risked operating plan and a clearer development arc for its radioenhancer JNJ-1900 (formerly...

Connect Biopharma reported a cluster of catalysts around its IL-4Rα antibody rademikibart: rapid-onset bronchodilation in a phase 1 intravenous...